H. -G. Meerpohl

Learn More
The role of cytoreductive surgery in relapsed ovarian cancer is not clearly defined. Therefore, patient selection remains arbitrary and depends on the center’s preference rather than on established selection criteria. The Descriptive Evaluation of preoperative Selection KriTeria for OPerability in recurrent OVARian cancer (DESKTOP OVAR) trial was undertaken(More)
PURPOSE The aim of this study was to assess whether the reduction in the total dose of pegylated liposomal doxorubicin (PLD) per cycle from 50 mg/m(2) every 4 weeks to 40 mg/m(2) every 4 weeks can effectively lower the incidence of treatment-related palmar-plantar erythrodysesthesia (PPE) and mucositis. METHODS Patients received PLD 40 mg/m(2) every 4(More)
PURPOSE Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer. We conducted a randomized phase II trial (TOWER [Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer])(More)
BACKGROUND Patients with metastatic breast cancer (MBC) are increasingly exposed to anthracyclines and taxanes either during treatment of primary breast cancer or during initial therapy of metastatic disease. The combination of gemcitabine and carboplatin was therefore investigated as an anthracycline- and taxane-free treatment option. PATIENTS AND(More)
 The most important cytotoxic drugs for the treatment of ovarian cancer, platinum compounds and paclitaxel, are known to induce neurotoxicity, which is dose limiting when higher paclitaxel doses are used or platinum-pretreated patients are treated. The absolute dose of paclitaxel per course has been demonstrated to be an important risk factor for the(More)
PURPOSE A high incidence of congestive heart failure (CHF) has been observed in patients with metastatic breast cancer (MBC) receiving doxorubicin-based chemotherapy and trastuzumab. The Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial evaluated trastuzumab plus cyclophosphamide and the less cardiotoxic anthracycline epirubicin. PATIENTS AND(More)
PURPOSE Previous phase II studies have indicated a greatly reduced hematotoxicity of docetaxel-based regimens administered on weekly schedules. The present trial was initiated to compare the toxicity and efficacy of weekly docetaxel versus its standard 3-weekly application in combination with doxorubicin. METHODS Patients previously untreated with(More)
Die apodiktische Aussage, dab sich an den Heilungsergebnissen, z.B. des Ovarialkarzinoms, seit Jahrzehnten nichts ge~indert habe, erscheint zwar h~tufig in spektakul~iren Vortr~igen, sie ist aber schon v o n d e r Sache her nicht ganz richtig: Aus 10 Klinikstatistiken bis 1948 ergibt sich eine mittlere 5-Jahrest~berlebensrate von 21%, aus 21 der Jahre 1960(More)
1101 Background: We investigated the toxicity and efficacy of weekly applied docetaxel compared to its standard 3-weekly application in pts previously untreated with chemotherapy for MBC. METHODS In the D2 trial (>60 yrs or KPS 60-80%), pts were randomized to receive docetaxel either on a 3-weekly (75 mg/m2 q3w) or on a weekly schedule (30 mg/m2 d1, 8, 15(More)
Die Bestimmung von Steroidrezeptoren bei Ovarialkarzinomen erscheint als Selektionsmethode nur von begrenztem Wert. Vorhersagen über eine Chemosensibilität aufgrund des Rezeptorstatus sind beim Ovarialkarzinom offensichtlich nicht möglich. In Übereinstimmung mit Befunden beim Mammakarzinom scheint aber eine Relation zwischen Rezeptorgehalt und Prognose zu(More)